Related Experiment Video
Updated: Jun 4, 2026

Assessment of DNA Double Strand Break Repair Activity Using High-throughput and Quantitative Luminescence-Based Reporter Assays
Published on: June 14, 2024
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable
Eduardo Vilar1, Catherine M Bartnik, Stephanie L Stenzel
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Abstract:
Microsatellite instability (MSI) is displayed by approximately 15% of colorectal cancers (CRC). Defective DNA mismatch repair generates mutations at repetitive DNA sequences such as those located in the double strand break (DSB) repair gene MRE11. We assessed the mutational status of MRE11 in a panel of 17 CRC cell lines and 46 primary tumors and found a strong correlation with MSI status in both cell lines and tumors. Therefore, we hypothesized that deficiency in MRE11 may sensitize CRC cells to poly(ADP-ribose) polymerase (PARP-1) inhibition based on the concept of synthetic lethality. We further assessed the activity of the PARP-1 inhibitor, ABT-888, in CRC cell lines and observed preferential cytotoxicity in those MSI cell lines harboring mutations in MRE11 compared with both wild-type cell lines and microsatellite stable (MSS) cell lines. A significant correlation between MRE11 expression levels and cytotoxicity to ABT-888 at 10 microM was observed (R² = 0.915, P < 0.001). Using two experimental approaches, including short hairpin RNA knocking down MRE11 in the wild-type and MSS cell line SW-480 and a second cell line model transfected with mutant MRE11, we experimentally tried to confirm the role of MRE11 in conferring sensitivity to PARP-1 inhibition. Both models led to changes in proliferation in response to ABT-888 at different concentrations, and a drug-response effect was not observed, suggesting a possible contribution of additional genes. We conclude that MSI colorectal tumors deficient in DSB repair secondary to mutation in MRE11 show a higher sensitivity to PARP-1 inhibition. Further clinical investigation of PARP-1 inhibitors is warranted in MSI CRCs.
Insights
Microsatellite instability (MSI) colorectal cancers with MRE11 mutations are sensitive to PARP-1 inhibitors. This suggests potential new treatments for MSI colorectal cancer (CRC) patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Microsatellite instability (MSI) occurs in ~15% of colorectal cancers (CRC).
- Defective DNA mismatch repair can lead to mutations in double-strand break (DSB) repair genes like MRE11.
- MRE11 mutations are correlated with MSI status in CRC cell lines and primary tumors.
Purpose of the Study:
- To investigate the hypothesis that MRE11 deficiency sensitizes CRC cells to poly(ADP-ribose) polymerase-1 (PARP-1) inhibition.
- To evaluate the efficacy of the PARP-1 inhibitor ABT-888 in CRC cell lines with varying MRE11 mutational status and MSI.
- To experimentally validate the role of MRE11 in conferring sensitivity to PARP-1 inhibition.
Main Methods:
- Assessed MRE11 mutational status in 17 CRC cell lines and 46 primary tumors.
- Administered PARP-1 inhibitor ABT-888 to CRC cell lines and measured cytotoxicity.
- Utilized short hairpin RNA (shRNA) to knockdown MRE11 in a wild-type/microsatellite-stable (MSS) cell line (SW-480).
- Transfected a cell line with mutant MRE11 to create a second experimental model.
Main Results:
- Found a strong correlation between MRE11 mutational status and MSI in CRC.
- Observed preferential cytotoxicity to ABT-888 in MSI CRC cell lines with MRE11 mutations.
- Demonstrated a significant correlation between MRE11 expression levels and ABT-888 cytotoxicity (R² = 0.915, P < 0.001).
- Experimental models showed proliferation changes in response to ABT-888, but a clear drug-response effect was not consistently observed, suggesting additional genetic factors.
Conclusions:
- MSI colorectal tumors with MRE11 deficiency exhibit heightened sensitivity to PARP-1 inhibition.
- MRE11 mutations may represent a predictive biomarker for PARP-1 inhibitor therapy in CRC.
- Further clinical investigation of PARP-1 inhibitors in MSI CRCs is warranted.
Related Concept Videos
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Nucleotide Excision Repair
Abnormal Proliferation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
